Integrated Network Pharmacology and Experimental Verification to Explore the Molecular Mechanism of Hedysarum Multijugum Maxim–Curcumae Rhizoma Herb Pair for Treating Non-Small Cell Lung Cancer

BackgroundHedysarum Multijugum Maxim–Curcumae Rhizoma (HMMCR), a well-known herb pair in traditional Chinese medicine (TCM), has been widely used for the treatment of various cancers. However, the active components of HMMCR and the underlying mechanism of HMMCR for non-small-cell lung carcinoma (NSC...

Full description

Bibliographic Details
Main Authors: Shaopu Hu, Mengxue Ge, Shuixiu Zhang, Min Jiang, Kaiwen Hu, Lei Gao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.854596/full
_version_ 1828854335708069888
author Shaopu Hu
Shaopu Hu
Mengxue Ge
Shuixiu Zhang
Shuixiu Zhang
Min Jiang
Min Jiang
Kaiwen Hu
Lei Gao
author_facet Shaopu Hu
Shaopu Hu
Mengxue Ge
Shuixiu Zhang
Shuixiu Zhang
Min Jiang
Min Jiang
Kaiwen Hu
Lei Gao
author_sort Shaopu Hu
collection DOAJ
description BackgroundHedysarum Multijugum Maxim–Curcumae Rhizoma (HMMCR), a well-known herb pair in traditional Chinese medicine (TCM), has been widely used for the treatment of various cancers. However, the active components of HMMCR and the underlying mechanism of HMMCR for non-small-cell lung carcinoma (NSCLC) remain unclear.MethodsActive ingredients of HMMCR were detected by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). On this basis, potential targets of HMMCR were obtained from SwissTargetPrediction database. NSCLC-related targets were collected from four public databases (GeneCards, OMIM, TTD, and PharmGkb). The drug ingredients–disease targets network was visualized. The hub targets between HMMCR and NSCLC were further analyzed by protein–protein interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Subsequently, the results predicted by network pharmacology were further validated via in vitro experiments.ResultsA total of 181 compounds were identified from the aqueous extract of HMMCR. Through network analysis, a compound–target network including 153 active ingredients of HMMCR and 756 HMMCR-NSCLC co-targets was conducted; 6 crucial compounds and 62 hub targets were further identified. The results of KEGG enrichment analysis showed that PI3K/Akt signaling pathway may be the critical pathway of HMMCR in the treatment of NSCLC. The in vitro experiments indicated that HMMCR inhibits the proliferation and migration of NSCLC cells via inactivation of the PI3K/Akt signaling pathway, consistent with the results predicted by network pharmacology.ConclusionIntegrating LC-ESI-MS/MS, network pharmacology approach, and in vitro experiments, this study shows that HMMCR has vital therapeutic effect on NSCLC through multi-compound, multi-target, and multi-pathway, which provides a rationale for using HMMCR for the treatment of NSCLC.
first_indexed 2024-12-13T00:31:08Z
format Article
id doaj.art-89b62db964c64bb09d82da3d26fefe79
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-12-13T00:31:08Z
publishDate 2022-03-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-89b62db964c64bb09d82da3d26fefe792022-12-22T00:05:19ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-03-011210.3389/fonc.2022.854596854596Integrated Network Pharmacology and Experimental Verification to Explore the Molecular Mechanism of Hedysarum Multijugum Maxim–Curcumae Rhizoma Herb Pair for Treating Non-Small Cell Lung CancerShaopu Hu0Shaopu Hu1Mengxue Ge2Shuixiu Zhang3Shuixiu Zhang4Min Jiang5Min Jiang6Kaiwen Hu7Lei Gao8Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Oncology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Integrated Management, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaBeijing University of Chinese Medicine, Beijing, ChinaDepartment of Oncology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Oncology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Integrated Management, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Oncology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Oncology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaBackgroundHedysarum Multijugum Maxim–Curcumae Rhizoma (HMMCR), a well-known herb pair in traditional Chinese medicine (TCM), has been widely used for the treatment of various cancers. However, the active components of HMMCR and the underlying mechanism of HMMCR for non-small-cell lung carcinoma (NSCLC) remain unclear.MethodsActive ingredients of HMMCR were detected by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). On this basis, potential targets of HMMCR were obtained from SwissTargetPrediction database. NSCLC-related targets were collected from four public databases (GeneCards, OMIM, TTD, and PharmGkb). The drug ingredients–disease targets network was visualized. The hub targets between HMMCR and NSCLC were further analyzed by protein–protein interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Subsequently, the results predicted by network pharmacology were further validated via in vitro experiments.ResultsA total of 181 compounds were identified from the aqueous extract of HMMCR. Through network analysis, a compound–target network including 153 active ingredients of HMMCR and 756 HMMCR-NSCLC co-targets was conducted; 6 crucial compounds and 62 hub targets were further identified. The results of KEGG enrichment analysis showed that PI3K/Akt signaling pathway may be the critical pathway of HMMCR in the treatment of NSCLC. The in vitro experiments indicated that HMMCR inhibits the proliferation and migration of NSCLC cells via inactivation of the PI3K/Akt signaling pathway, consistent with the results predicted by network pharmacology.ConclusionIntegrating LC-ESI-MS/MS, network pharmacology approach, and in vitro experiments, this study shows that HMMCR has vital therapeutic effect on NSCLC through multi-compound, multi-target, and multi-pathway, which provides a rationale for using HMMCR for the treatment of NSCLC.https://www.frontiersin.org/articles/10.3389/fonc.2022.854596/fullHedysarum Multijugum MaximCurcumae Rhizomanetwork pharmacologyPI3K/Akt signaling pathwayNSCLC
spellingShingle Shaopu Hu
Shaopu Hu
Mengxue Ge
Shuixiu Zhang
Shuixiu Zhang
Min Jiang
Min Jiang
Kaiwen Hu
Lei Gao
Integrated Network Pharmacology and Experimental Verification to Explore the Molecular Mechanism of Hedysarum Multijugum Maxim–Curcumae Rhizoma Herb Pair for Treating Non-Small Cell Lung Cancer
Frontiers in Oncology
Hedysarum Multijugum Maxim
Curcumae Rhizoma
network pharmacology
PI3K/Akt signaling pathway
NSCLC
title Integrated Network Pharmacology and Experimental Verification to Explore the Molecular Mechanism of Hedysarum Multijugum Maxim–Curcumae Rhizoma Herb Pair for Treating Non-Small Cell Lung Cancer
title_full Integrated Network Pharmacology and Experimental Verification to Explore the Molecular Mechanism of Hedysarum Multijugum Maxim–Curcumae Rhizoma Herb Pair for Treating Non-Small Cell Lung Cancer
title_fullStr Integrated Network Pharmacology and Experimental Verification to Explore the Molecular Mechanism of Hedysarum Multijugum Maxim–Curcumae Rhizoma Herb Pair for Treating Non-Small Cell Lung Cancer
title_full_unstemmed Integrated Network Pharmacology and Experimental Verification to Explore the Molecular Mechanism of Hedysarum Multijugum Maxim–Curcumae Rhizoma Herb Pair for Treating Non-Small Cell Lung Cancer
title_short Integrated Network Pharmacology and Experimental Verification to Explore the Molecular Mechanism of Hedysarum Multijugum Maxim–Curcumae Rhizoma Herb Pair for Treating Non-Small Cell Lung Cancer
title_sort integrated network pharmacology and experimental verification to explore the molecular mechanism of hedysarum multijugum maxim curcumae rhizoma herb pair for treating non small cell lung cancer
topic Hedysarum Multijugum Maxim
Curcumae Rhizoma
network pharmacology
PI3K/Akt signaling pathway
NSCLC
url https://www.frontiersin.org/articles/10.3389/fonc.2022.854596/full
work_keys_str_mv AT shaopuhu integratednetworkpharmacologyandexperimentalverificationtoexplorethemolecularmechanismofhedysarummultijugummaximcurcumaerhizomaherbpairfortreatingnonsmallcelllungcancer
AT shaopuhu integratednetworkpharmacologyandexperimentalverificationtoexplorethemolecularmechanismofhedysarummultijugummaximcurcumaerhizomaherbpairfortreatingnonsmallcelllungcancer
AT mengxuege integratednetworkpharmacologyandexperimentalverificationtoexplorethemolecularmechanismofhedysarummultijugummaximcurcumaerhizomaherbpairfortreatingnonsmallcelllungcancer
AT shuixiuzhang integratednetworkpharmacologyandexperimentalverificationtoexplorethemolecularmechanismofhedysarummultijugummaximcurcumaerhizomaherbpairfortreatingnonsmallcelllungcancer
AT shuixiuzhang integratednetworkpharmacologyandexperimentalverificationtoexplorethemolecularmechanismofhedysarummultijugummaximcurcumaerhizomaherbpairfortreatingnonsmallcelllungcancer
AT minjiang integratednetworkpharmacologyandexperimentalverificationtoexplorethemolecularmechanismofhedysarummultijugummaximcurcumaerhizomaherbpairfortreatingnonsmallcelllungcancer
AT minjiang integratednetworkpharmacologyandexperimentalverificationtoexplorethemolecularmechanismofhedysarummultijugummaximcurcumaerhizomaherbpairfortreatingnonsmallcelllungcancer
AT kaiwenhu integratednetworkpharmacologyandexperimentalverificationtoexplorethemolecularmechanismofhedysarummultijugummaximcurcumaerhizomaherbpairfortreatingnonsmallcelllungcancer
AT leigao integratednetworkpharmacologyandexperimentalverificationtoexplorethemolecularmechanismofhedysarummultijugummaximcurcumaerhizomaherbpairfortreatingnonsmallcelllungcancer